oxfendazole
Small moleculeexperimental
Oxfendazole is a broad-spectrum benzimidazole anthelmintic. Its main use is for protecting livestock against roundworm, strongyles, and pinworms. Oxfendazole is the sulfoxide metabolite of fenbendazole. Like mebendazole, oxfendazole inhibits tubulin polymerization. — Wikipedia
Clinical trial activity
7 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02234570)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)Nc1nc2cc([S+]([O-])c3ccccc3)ccc2[nH]1- Mol. weight
- 315.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOxfendazole ↗
- ChEMBLCHEMBL42442 ↗
Also known as
- methyl 5(6)-phenylsulfinyl-2-benzimidazolecarbamate
- oxfendazole
- oxfendazole
- oxfendazole
- oxfendazole
- oxfendazole monohydrochloride
- rs 8858
- rs-8858
- rs-8858
- synanthic
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04920292 | Phase 1 | Dec 1, 2021 | Drugs for Neglected Diseases Initiative, Ifakara Health Institute, Swiss TPH, University of Basel |
| NCT04713787 | Phase 2 | Sep 8, 2021 | Asociacion Benefica Prisma, National Institutes of Health (NIH), University of Iowa, University of Virginia |
| NCT03435718 | Phase 2 | Oct 31, 2018 | Cayetano Heredia University, Oxfendazole Development Group |
| NCT02636803 | Phase 2 | Nov 1, 2017 | Cayetano Heredia University, Johns Hopkins University, University of Milano Bicocca |
| NCT03035760 | Phase 1 | May 12, 2017 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01584362 | Phase 1 | Aug 1, 2016 | Cayetano Heredia University, Johns Hopkins University, University of Milano Bicocca |
| NCT02234570 | Phase 1 | Nov 1, 2014 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cayetano Heredia University | Academic/Hospital | 3 | 0 | 2 | 2016 |
| Johns Hopkins University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2014 |
| University of Milano Bicocca | Academic/Hospital | 2 | 0 | 2 | 2016 |
| Asociacion Benefica Prisma | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Drugs for Neglected Diseases Initiative | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Ifakara Health Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2021 |
| Oxfendazole Development Group | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Swiss TPH | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Basel | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Virginia | Academic/Hospital | 1 | 0 | 1 | 2021 |
13 organizations
Page 1 / 1